Adma Biologics (ADMA) Net Income towards Common Stockholders Growth (5y) (2016 - 2025)
Adma Biologics (ADMA) Net Income towards Common Stockholders Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Adma Biologics | 2.04 Bn | 1.95 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -43.53% |
| Sep 30, 2025 | 32.97% |
| Jun 30, 2025 | 29.88% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | 44.41% |
| Sep 30, 2024 | 38.76% |
| Jun 30, 2024 | 33.08% |
| Mar 31, 2024 | 26.33% |
| Dec 31, 2023 | 20.97% |
| Sep 30, 2023 | 16.76% |
| Jun 30, 2023 | 15.45% |
| Mar 31, 2023 | 17.56% |
| Dec 31, 2022 | -9.64% |
| Sep 30, 2022 | 0.46% |
| Jun 30, 2022 | -9.81% |
| Mar 31, 2022 | -22.69% |
| Dec 31, 2021 | -37.77% |
| Sep 30, 2021 | -27.14% |
| Jun 30, 2021 | -25.62% |
| Mar 31, 2021 | -31.79% |